For the Inventor, By the Inventor

Enter assignee name

Asahi Kasei Pharma Corporation

USPTO Granted Patents = 81

CIPO Patents = 3

EPO Patents = 43

Trademarks = 1

Forward Citations = 234

Loading Chart...

Loading Chart...

115 inventors (with patents filed for the assignee):

Motoshi Shoda (7 out of 8 patents)

Takeshi Matsuoka (6 out of 6 patents)

Rintaro Yamada (6 out of 6 patents)

4. Minoru Seto (6 out of 11 patents)

5. Takuji Kouzuma (6 out of 6 patents)

6. Shigeyuki Imamura (5 out of 6 patents)

7. Koki Matsubara (5 out of 5 patents)

8. Shiro Miyoshi (5 out of 12 patents)

9. Shinichi Sakasegawa (4 out of 5 patents)

10. Fumihide Nishio (4 out of 4 patents)

11. Kazuhisa Tsuruta (4 out of 4 patents)

12. Yoshikazu Aoki (4 out of 5 patents)

13. Yutaka Osawa (4 out of 5 patents)

14. Inder Kaul (4 out of 4 patents)

15. Hiroshi Kuriyama (4 out of 6 patents)

Core Competencies:

P2X7 Receptor Antagonists

Nicotinamide Mononucleotide

Cyclic Compounds

Peripheral Neuropathy

Teriparatide

Soluble Thrombomodulin

Pulmonary Arterial Hypertension

Phenylpropionic Acid Derivatives

Indazole Derivatives

Sulfonamide Compounds

Glycated Proteins

Protease Screening

81 patents: Sort by Forward Citations

1. 12295947 - Tetrahydroquinoline derivatives as P2X7 receptor antagonists (2025-05-13),

2. 11959116 - Method for producing nicotinamide mononucleotide (2024-04-16),

3. 11667630 - Nitrogen-containing 6-membered cyclic compound (2023-06-06),

4. 11541104 - Method for preventing or treating osteoporosis, characterized by administering teriparatide or salt thereof at a frequency of twice a week (2023-01-03),

5. 11497795 - Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent (2022-11-15),

6. 11439633 - Tetrahydroquinoline derivatives as P2X7 receptor antagonists (2022-09-13),

7. 11077100 - Tetrahydroquinoline derivatives as P2X7 receptor antagonists (2021-08-03),

8. 10988468 - Nitrogen-containing 6-membered cyclic compound (2021-04-27),

9. 10975411 - Method and reagent for measuring mevalonic acid, 3-hydroxymethylglutaryl coenzyme A, and coenzyme A (2021-04-13),

10. 10900063 - Measurement of Lp-PLAactivity (2021-01-26),

11. 10709767 - Agent for prophylactic and/or therapeutic treatment of peripheral neuropathic pain caused by anticancer agent (2020-07-14),

12. 10683335 - Freeze-dried preparation containing high-purity PTH and method for producing same (2020-06-16),

13. 10588945 - Agent for preventing onset of idiopathic osteonecrosis of femoral head and/or suppressing progress of same (2020-03-17),

14. 10472665 - Measuring method and composition using kinase (2019-11-12),

15. 10011643 - Freeze-dried preparation containing high-purity PTH and method for producing same (2018-07-03),

Asahi Kasei Pharma Corporation is a subsidiary of Asahi Kasei Corporation and specializes in the pharmaceutical business. They are committed to improving the health and well-being of people worldwide through the development and commercialization of innovative pharmaceutical products. With a focus on ethical and reliable practices, Asahi Kasei Pharma Corporation aims to contribute to society by providing high-quality and effective healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

81 Patents

#540 in Tokyo

#1,262 in Japan

#9,086 in the World

Asahi Kasei Pharma Corporation

Forward Citations = 234

115 inventors:

Motoshi Shoda (7 out of 8 patents)

Takeshi Matsuoka (6 out of 6 patents)

Rintaro Yamada (6 out of 6 patents)

4. Minoru Seto (6 out of 11 patents)

5. Takuji Kouzuma (6 out of 6 patents)

Please report any incorrect information to support@idiyas.com

Loading…